Pindolol (versus unexposed)

Study	Type of data	Exposure measurement	Outcome assessment	Adjustment
Medveczky, 2004	case control	Exposure data collected from 3 sources: a post-paid structured questionnaire sent to the parents requesting drugs taken during pregnancy, according to gestational months; maternal prenatal care logbook (in which obstetricians must record all prescribed drugs); nurses visited non-responding families.	The Hungarian Congenital Abnormality Registry (HCAR), in which notification by physicians of cases with Congenital anomalies is mandatory (including infant deaths and usual stillborn fetuses). Controls were selected from the National Birth Registry of the Central Statistical Office.	Controls matched according to sex, birth week, and district of parents' residence. Multivariable unconditional logistic regression model for maternal age, birth order, and employment status.
Rosenfeld, 1986	randomized controlled trial	Patients were randomly allocated to one of two groups, who were treated with either hydralazine alone, or with hydralazine combined with pindolol.	Placental and fetal growth rate were monitored by serial plasma estriol estimations and ultrasonography of the fetal biparietal diameter. Cardiotocography was performed at weekly intervals from the 34th wk of gestation or in case of complications. The status of the neonate at birth was assessed.	No adjustment. Randomisation. Patients were excluded from the study if they suffered from obstructive lung disease, insulin-dependent diabetes or any other condition constituting a contraindication for therapy with hydralazine or pindolol.

master protocol